IP Verse

Combination Products With Tyrosine Kinase Inhibitors And Their Use - EP2834246

The patent EP2834246 was granted to Novartis on Jul 28, 2021. The application was originally filed on Apr 3, 2013 under application number EP13772621A. The patent is currently recorded with a legal status of "Revoked".

EP2834246

NOVARTIS
Application Number
EP13772621A
Filing Date
Apr 3, 2013
Status
Revoked
Jul 21, 2023
Publication Date
Jul 28, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

D YOUNGApr 28, 2022D YOUNGADMISSIBLE

Patent Citations (150) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0409595
DESCRIPTIONEP0424021
DESCRIPTIONEP0520722
DESCRIPTIONEP0564409
DESCRIPTIONEP0566226
DESCRIPTIONEP0769947
DESCRIPTIONEP0787722
DESCRIPTIONEP0837063
DESCRIPTIONEP1052264
DESCRIPTIONEP1241176
DESCRIPTIONJP2004107299
DESCRIPTIONUS2007265272
DESCRIPTIONUS3714357
DESCRIPTIONUS4636505
DESCRIPTIONUS5093330
DESCRIPTIONUS5171744
DESCRIPTIONUS5451700
DESCRIPTIONUS5461076
DESCRIPTIONUS5616582
DESCRIPTIONUS5747498
DESCRIPTIONUS6166037
DESCRIPTIONUS6391874
DESCRIPTIONUS6552065
DESCRIPTIONUS6713485
DESCRIPTIONUS6727256
DESCRIPTIONUS6828320
DESCRIPTIONUS7157466
DESCRIPTIONWO0000531
DESCRIPTIONWO0009495
DESCRIPTIONWO0023457
DESCRIPTIONWO0027819
DESCRIPTIONWO0027820
DESCRIPTIONWO0031048
DESCRIPTIONWO0037502
DESCRIPTIONWO0059509
DESCRIPTIONWO0066558
DESCRIPTIONWO0066559
DESCRIPTIONWO0075114
DESCRIPTIONWO0077018
DESCRIPTIONWO0078774
DESCRIPTIONWO0104118
DESCRIPTIONWO0113953
DESCRIPTIONWO0123399
DESCRIPTIONWO0127130
DESCRIPTIONWO0127131
DESCRIPTIONWO0160835
DESCRIPTIONWO0194368
DESCRIPTIONWO0200652
DESCRIPTIONWO0200676
DESCRIPTIONWO0200679
DESCRIPTIONWO02051841
DESCRIPTIONWO02053564
DESCRIPTIONWO02088167
DESCRIPTIONWO02092599
DESCRIPTIONWO02096462
DESCRIPTIONWO02100879
DESCRIPTIONWO0210143
DESCRIPTIONWO0212266
DESCRIPTIONWO0222577
DESCRIPTIONWO0222630
DESCRIPTIONWO0242298
DESCRIPTIONWO03000840
DESCRIPTIONWO03013541
DESCRIPTIONWO03033495
DESCRIPTIONWO03035668
DESCRIPTIONWO03039544
DESCRIPTIONWO03048181
DESCRIPTIONWO03053966
DESCRIPTIONWO03062259
DESCRIPTIONWO03064445
DESCRIPTIONWO03072592
DESCRIPTIONWO03082280
DESCRIPTIONWO03082787
DESCRIPTIONWO03086408
DESCRIPTIONWO03087094
DESCRIPTIONWO03099807
DESCRIPTIONWO03104195
DESCRIPTIONWO03104204
DESCRIPTIONWO03104205
DESCRIPTIONWO2004000814
DESCRIPTIONWO2004000839
DESCRIPTIONWO2004005229
DESCRIPTIONWO2004005258
DESCRIPTIONWO2004005285
DESCRIPTIONWO2004016601
DESCRIPTIONWO2004018422
DESCRIPTIONWO2004018425
DESCRIPTIONWO2004018431
DESCRIPTIONWO2004018449
DESCRIPTIONWO2004018450
DESCRIPTIONWO2004018451
DESCRIPTIONWO2004018457
DESCRIPTIONWO2004018465
DESCRIPTIONWO2004019944
DESCRIPTIONWO2004019945
DESCRIPTIONWO2004026841
DESCRIPTIONWO2004026873
DESCRIPTIONWO2004033412
DESCRIPTIONWO2004037805
DESCRIPTIONWO2004039762
DESCRIPTIONWO2004039766
DESCRIPTIONWO2004045607
DESCRIPTIONWO2004045618
DESCRIPTIONWO2004046083
DESCRIPTIONWO2005028443
DESCRIPTIONWO2007019933
DESCRIPTIONWO2007075567
DESCRIPTIONWO2008008539
DESCRIPTIONWO2008051808
DESCRIPTIONWO2008064157
DESCRIPTIONWO2011018454
DESCRIPTIONWO9219594
DESCRIPTIONWO9319749
DESCRIPTIONWO9319750
DESCRIPTIONWO9319751
DESCRIPTIONWO9410202
DESCRIPTIONWO9417090
DESCRIPTIONWO9503283
DESCRIPTIONWO9602543
DESCRIPTIONWO9602553
DESCRIPTIONWO9630347
DESCRIPTIONWO9633980
DESCRIPTIONWO9702266
DESCRIPTIONWO9730034
DESCRIPTIONWO9738983
DESCRIPTIONWO9749688
DESCRIPTIONWO9810767
DESCRIPTIONWO9811223
DESCRIPTIONWO9818796
DESCRIPTIONWO9828319
DESCRIPTIONWO9835958
DESCRIPTIONWO9903854
DESCRIPTIONWO9916766
DESCRIPTIONWO9917804
DESCRIPTIONWO9924449
DESCRIPTIONWO9924450
DESCRIPTIONWO9924451
DESCRIPTIONWO9935146
DESCRIPTIONWO9938877
DESCRIPTIONWO9941267
DESCRIPTIONWO9967263
DESCRIPTIONWO9967264
DESCRIPTIONWO9967265
DESCRIPTIONWO9967266
INTERNATIONAL-SEARCH-REPORTWO2008064157
INTERNATIONAL-SEARCH-REPORTWO2011018454
OPPOSITIONWO2008064157
OPPOSITIONWO2009143211
OPPOSITIONWO2011018454
SEARCHWO2009143211

Non-Patent Literature (NPL) Citations (14) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Schiller J H, Et Al, "Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC", 2010 ASCO Annual Meeting II, Journal of Clinical Oncology, (20100620), vol. 28, no. 18Supp, pages 1 - 4, XP055923024
OPPOSITION- U.S. National Library Of Medicine, "History of Changes for Study: NCT01244191 ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer", ClinicalTrials.gov archive, (20120321), pages 1 - 25, XP055923017
OPPOSITION- WAKELEE et al., "A phase Ib/ll study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC", Journal of Clinical Oncology, (20100520), vol. 28, page 15, XP002714870
OPPOSITION- West Howard, "ARQ 197:Novel c-MET inhibitor shows promise in early clinical trial results with Tarceva", Global Resource for Advancing Cancer Education, (20100204), pages 1 - 6, XP055923020
OPPOSITION- Zhang Ying, Et Al, "XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC", IDrugs, (20100201), vol. 13, no. 2, pages 112 - 121, XP055923006
OPPOSITION- JANNE et al., "Targeting MET with XL184 to reverse EGFR tyrosine kinase inhibitor (TKI) resistance in NSCLC: impact of preclinical studies on clinical trial design", 20th EORTC-NCI-AACR symposium, abstract published in Eur. J. Cancer, (20081024), vol. 6, no. 12, doi:10.1016/S1359-6349(08)72486-8, page 174, XP025534616
OPPOSITION- XU et al., "Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor- 1alpha in non-small cell lung cancer cells", Oncogene, (20100000), vol. 29, doi:10.1038/onc.2010.16, pages 2616 - 2627, XP037744533
OPPOSITION- DULAK et al., "HGF-independent Potentiation of EGFR action by c-MET", Oncogene, (20110000), vol. 30, no. 33, doi:10.1038/onc.2011.84, pages 3625 - 3635, XP055193257
OPPOSITION- TANG et al., "Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer", British Journal of Cance r, (20080000), vol. 99, doi:10.1038/sj.bjc.6604559, pages 911 - 922, XP009111371
OPPOSITION- ENGLEMAN et al., "METAmplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling", Science, (20070518), vol. 316, doi:10.1126/science.1141478, pages 1039 - 1043, XP002498405
OPPOSITION- U. Mcdermott, R. V. Pusapati, J. G. Christensen, N. S. Gray, J. Settleman, "Acquired Resistance of Non-Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor Dependency", Cancer research, (20100215), vol. 70, no. 4, doi:10.1158/0008-5472.CAN-09-3620, ISSN 00085472, pages 1625 - 1634, XP055095190
OPPOSITION- LIU et al., "A Novel Kinase Inhibitor, INCB28060, Blocks c- MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3", Clin Cancer Res, (20110914), vol. 17, no. 22, doi:10.1158/1078-0432.CCR-11-1157, pages 7127 - 7138, XP055030185
OPPOSITION- Y AKES et al., "Cabozantinib (XL 184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth", Mol Cancer Ther, (20111200), vol. 10, no. 12, doi:10.1158/1535-7163.MCT-11-0264, pages 2298 - 2308, XP055031202
OPPOSITION- PURI et al., "Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer", Journal of Carcinogenesis, (20081205), vol. 7, no. 9, doi:10.4103/1477-3163.44372, pages 1 - 8, XP008122308

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents